Leah B. Sansbury, Ph.D., M.S.P.H.
Program Director, Clinical and Translational Epidemiology Branch
Contact Information
Epidemiology and Genetics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
6130 Executive Blvd., Rm. 5106, MSC 7324
Bethesda, MD 20892-7324
(For express delivery, use Rockville, MD 20852)
telephone: (301) 435-4910
fax: (301) 402-4279
e-mail: sansburl@mail.nih.gov
Interest Areas
Molecular epidemiology, clinical epidemiology, pharmacoepidemiology, and pharmacogenetics.
Degrees
Ph.D. – Epidemiology
University of North Carolina (UNC) at Chapel Hill School of Public Health
M.S.P.H.
University of North Carolina (UNC) at Chapel Hill School of Public Health
B.S.- Biology
James Madison University
Biography
Dr. Sansbury is a Program Director in the Epidemiology and Genetics Research Program's (EGRP) Clinical and Translational Epidemiology Branch (CTEB). She is responsible for a research portfolio and initiatives that focus on etiologic and genetic factors that influence cancer progression, recurrence, survival and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions. She also has an adjunct research appointment in the Nutritional Epidemiology Branch in NCI's intramural Division of Cancer Epidemiology and Genetics (DCEG).
She is the EGRP liaison to the Epidemiology of Endometrial Cancer Consortium (E2C2) and the Pancreatic Cancer Cohort Consortium (PanScan). Dr. Sansbury is also a Division of Cancer Control and Population Sciences (DCCPS) representative to the NCI - Food and Drug Administration (FDA) Interagency Oncology Task Force (IOTF).
Dr. Sansbury is a DCCPS representative to the Pharmacogenetics Research Network (PGRN) Steering Committee, a member of the Trans-NCI Pharmacoepidemiology and Pharmacogenetics Working Group (PPWG), and Co-Chair of its Population Science Subgroup.
She joined EGRP in 2007 as a Program Director in its Modifiable Risk Factors Branch (MRFB) and transferred to CTEB in 2009. She had been an NCI Cancer Prevention Fellow and worked in the Institute's Laboratory of Cancer Prevention, Center for Cancer Research. Her research focused on whether inflammatory cytokine gene polymorphisms influenced serum biomarkers of inflammation, and whether these polymorphisms modified the associations between lifestyle factors, including use of nonsteroidal anti-inflammatory drugs (NSAIDs), in relation to adenoma recurrence in the Polyp Prevention Trial. Much of Dr. Sansbury's research to date has focused on combining molecular and genetic information with data on lifestyle and exposure factors in epidemiologic studies on colon cancer in order to investigate associations related to the inflammatory pathway and immune response.
